𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Doorway-provoked freezing of gait in Parkinson's disease

✍ Scribed by Dorothy Cowie; Patricia Limousin; Amy Peters; Marwan Hariz; Brian L. Day


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
460 KB
Volume
27
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Freezing of gait in Parkinson's disease can be difficult to study in the laboratory. Here we investigate the use of a variable‐width doorway to provoke freeze behavior together with new objective methods to measure it. With this approach we compare the effects of anti‐parkinsonian treatments (medications and deep‐brain stimulation of the subthalamic nucleus) on freezing and other gait impairments. Ten “freezers” and 10 control participants were studied. Whole‐body kinematics were measured while participants walked at preferred speed in each of 4 doorway conditions (no door present, door width at 100%, 125%, and 150% of shoulder width) and in 4 treatment states (offmeds/offstim, offmeds/onstim, onmeds/offstim, onmeds/onstim). With no doorway, the Parkinson's group showed characteristic gait disturbances including slow speed, short steps, and variable step timing. Treatments improved these disturbances. The Parkinson's group slowed further at doorways by an amount inversely proportional to door width, suggesting a visuomotor dysfunction. This was not improved by either treatment alone. Finally, freeze‐like events were successfully provoked near the doorway and their prevalence significantly increased in narrower doorways. These were defined clinically and by 2 objective criteria that correlated well with clinical ratings. The risk of freeze‐like events was reduced by medication but not by deep‐brain stimulation. Freeze behavior can be provoked in a replicable experimental setting using the variable‐width doorway paradigm, and measured objectively using 2 definitions introduced here. The differential effects of medication and deep‐brain stimulation on the gait disturbances highlight the complexity of Parkinsonian gait disorders and their management. © 2011 Movement Disorder Society


📜 SIMILAR VOLUMES


The clinical spectrum of freezing of gai
✍ Yasuyuki Okuma; Nobuo Yanagisawa 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

Freezing of gait (FOG) is a common and very disabling symptom in Parkinson's disease (PD). It is usually observed in the advanced stage of the disease, although a mild form can be seen in the early stage. Although some studies have suggested that longer duration of dopaminergic treatment is associat

Effects of caffeine on the freezing of g
✍ Mayumi Kitagawa; Hideki Houzen; Kunio Tashiro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB 👁 1 views

## Abstract Caffeine is a nonselective competitive blockade of adenosine A1 and A2A receptors. In this report, we studied the efficacy of 100 mg of caffeine per day on the freezing of gait (FOG) for patients with Parkinson's disease. Different subtypes of FOG showed different therapeutic responses

Freezing of gait and executive functions
✍ Marianna Amboni; Autilia Cozzolino; Katia Longo; Marina Picillo; Paolo Barone 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views

## Abstract Freezing of gait (FOG) is a frequent, disabling symptom of Parkinson's disease (PD). FOG usually lasts a few seconds. It refers to brief paroxysmal events during which a subject is unable to start or continue locomotion. Despite its frequency, FOG pathophysiology is unclear. Because a f

Validation of the freezing of gait quest
✍ Nir Giladi; Joseph Tal; Tali Azulay; Oliver Rascol; David J. Brooks; Eldad Melam 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and afte